GlassScriptPhysician profile
Neil Batta
NPI 1841653540
$1,603.44
in general payments reported to CMS, 2019-2025
14 companies · $177 in 2025
The $177 reported for 2025 was less than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $549 · 2022: $477 · 2023: $375 · 2024: $25.59 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $578.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $577.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $650.38 | 2021-2023 | Senza |
| Boston Scientific Corporation | $300.21 | 2023-2025 | General - Pain Management |
| Zimvie INC. | $266.58 | 2022 | |
| Spr Therapeutics, INC | $66.50 | 2022 | |
| Relievant Medsystems, INC. | $57.88 | 2023 | Intracept |
| Collegium Pharmaceutical, INC. | $57.26 | 2022-2023 | Belbuca, Xtampza |
| Medtronic, INC. | $47.21 | 2022-2023 | Intellis Adaptivestim |
| Arteriocyte Medical Systems, INC. | $37.11 | 2022 | |
| Zimmer Biomet Holdings, INC. | $26.42 | 2025 | Gel-One Cross-Linked Hyaluronate |
| Nalu Medical, INC. | $25.59 | 2024 | Nalu Neurostimulation System |
| Pfizer INC. | $19.34 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $19.32 | 2023 | |
| Abbvie INC. | $17.38 | 2023 | Botox |
| Baxter Healthcare | $12.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Batta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.